Vertex adds Lonza to cautious Casgevy commercial network
Autologous, ex vivo CRISPR/Cas9 gene-edited therapy Casgevy won US Food and Drug Administration (FDA) approval in December 2023 to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). However, akin to other advanced therapy …